# The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

> **NCT04262427** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Christie NHS Foundation Trust** · enrollment: 21 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide 50mg
- **DRUG:** Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]

## Key facts

- **NCT ID:** NCT04262427
- **Lead sponsor:** The Christie NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-28
- **Primary completion:** 2023-10-28
- **Final completion:** 2024-04-28
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262427, "The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04262427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*